Etoposide

製品コードS1225 別名:VP-16, VP-16213

Etoposide化学構造

分子量(MW):588.56

Etoposide is a semisynthetic derivative of podophyllotoxin, which inhibits DNA synthesis via topoisomerase II inhibition activity.

サイズ 価格(税別)  
JPY 15106.00
JPY 11620.00
JPY 46480.00

カスタマーフィードバック(6)

  • ABT-199 synergizes strongly with lymphoma chemotherapy agents that affect MCL1 levels. Viability and CI vs Fa after 24-h exposure to etoposide alone or in combination with ABT-199 in Riva, U2932 and VavP-Bcl2/c-MYC murine tumor cells. Viability shown at 500 nM.

    Leukemia, 2015, 29: 1702–1712. Etoposide purchased from Selleck.

    Dox promotes formation of DNA DSBs in primary neurons. (A) Cortical neurons at 28–32 DIV were treated with a vehicle or with Dox (0.1 μ M) or with DNA damaging drug etoposide (5 μ M) overnight, fixed, and stained for a marker of DSBs phosphorylated histone H2A variant X, γ H2A.X (green), MAP2c (red), and with the nuclear Hoechst dye (blue), and imaged. The neuronal nucleus is enlarged on the Dox panel to illustrate the γ H2A.X puncta. Note the green nuclear staining in cells treated with Dox and etoposide. Also note the reduced dendritic arborization in neurons treated with Dox and etoposide. Scale bar is 20 μm.

    Sci Rep, 2016, 6:25705.. Etoposide purchased from Selleck.

  • Viability of U87 cells(C) assessed by the Alamar blue assay, 72 h after transfection with siRNA anti-survivin (siSURV) or with siMUT and/or cell incubation with the chemotherapeutical drugs etoposide (ETO) and Bliss interaction index (D) determined for the combined effects on cell viability of survivin silencing plus treatment with each drug. Cells were transfected, for 4 h, with (14Ser)2N5/siRNA/HL complexes and, after an additional period of 20 h, cells were incubated with 1.5 μM ETO (C) for 48 h. Results, representative of at least three independent experiments, are expressed as a percentage of the nontreated control cells. Combined treatment (dotted bar) was compared with the single drug treatment (gray bar) (**p < 0.01, ***p < 0.001) and the Bliss interaction index of each combined treatment was compared with the theoretical value expected for an additive effect (1.0) (#p < 0.05, ns, non-significant).

    Eur J Pharm Biopharm, 2016, 104:7-19.. Etoposide purchased from Selleck.

    Cellular biomarker responses in HT29 cells exposed to various cytotoxic chemotherapeutic agents in combination with the Chk1 inhibitor V158411. HT29 cells were exposed to the combination GI80 of gemcitabine (0.2 uM), camptothecin (0.44 uM), cisplatin (68 uM), oxaliplatin (131 uM), doxorubicin (1.2 uM) or etoposide (59 uM) for 18 hours followed by DMSO (-) or 400 nM V158411 (+) for a further 24 hours. Protein expression was characterized by immunoblotting.

    BMC Cancer 2014 14, 483. Etoposide purchased from Selleck.

  • (c) and (d) Effects of fractions C4 and C5 on topoisomerase II activity. Topoisomerase II activity was measured by plasmid DNA cleavage assay. DNA bands were visualized using UV light and the intensity of linear DNA band in each lane was measured using imageJ software. Lane 1: plasmid PBR322DNA. Lane 2: control, topoisomerase II + plasmid PBR322DNA. Lanes 3, 4, and 5: 40, 20, and 10 μg/mL fraction C4 + plasmid PBR322DNA, respectively. Lanes 6, 7, and 8: 40, 20, and 10 μg/mL fraction C5 + plasmid PBR322DNA, respectively. Lane 9: 100 μM etoposide + plasmid PBR322DNA. The data in different groups were expressed as the mean ± SD from 3 experiments. Statistical difference between groups was assessed by t-test using SPSS 20.0. ∗∗P < 0.01 versus the control group.

    Evid Based Complement Alternat Med, 2017, 2017:1456786. Etoposide purchased from Selleck.

    Effects of etoposide on the radiosensitivities of cholangiocarcinoma cell lines. The cell survival curves of (A) KKU-M055 and (B) KKU-M214 cells were obtained from clonogenic survival assays. The cells were treated with X-ray irradiation or etoposide (0.025 or 0.05 µg/ml) alone or pretreated with etoposide for 24 h prior to X-ray irradiation. Survival fractions were determined at day 10 following X-ray irradiation. The dose-response curves depict the mean ± standard deviation of survival fractions of three independent experiments. IR, irradiation.

    Oncol Lett, 2018, 15(3):3895-3903. Etoposide purchased from Selleck.

製品安全説明書

Topoisomerase阻害剤の選択性比較

生物活性

製品説明 Etoposide is a semisynthetic derivative of podophyllotoxin, which inhibits DNA synthesis via topoisomerase II inhibition activity.
ターゲット
Topo II [2]
(Cell-free assay)
体外試験

Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA, which induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. [1] Etoposide inhibits the growth of murine angiosarcoma cell line (ISOS-1) in a 5 days-period with IC50 of 0.25 μg/mL. Cell growth of normal murine microvascular endothelial cells (mECs) is less sensitive to Etoposide with IC50 of 10 μg/mL). [2] Etoposide treated for 6 hr inhibits colonies of tetraploid variant of the human leukemic lymphoblast line CCRF-CEM with IC50 of 0.6 μM. [3] Etoposide treated for 2 hr inhibits growth of human pancreatic cancer cell line Y1, Y3, Y5, Y19, YM. YS, and YT with IC50s of 300 μg/mL, 300 μg/mL, 300 μg/mL, 91 μg/mL, 0.68 μg/mL, 300 μg/mL, 300 μg/mL, and 260 μg/mL, respectively. [4] Etoposide exposed for 1 hr inhibits growth of human glioma cell lines CL5, G142, G152, G111, and G5 with IC50 of 8, 9, 9.8, 10, and 15.8 μg/mL respectively for 12 days. Under same condition, the IC90 value is attained in cell lines CL5, G152, G142, and G111 at 26, 27, 32, and 33 μg/mL. Etoposide inhibition of topoisomerase II is homogeneous for each cell. The average inhibition rates are 15%, 21.8%, 31.8%, 41.5%, and 49.5% for 1, 2, 4, 8, and 16 μg Etoposide, respectively. [5]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Kelly M3TH[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlK0TWM2OD1yLkGy5qCKyrIkgJmwMlAyKM7:TR?= MmSzNlU6PjB{OEK=
KellyCis83 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTBwMUdihKnDueLCiUCuNFIh|ryP NIjm[oMzPTl4MEK4Ni=>
SK-N-AS NXLDcWFJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LmemlEPTB;MD6yOQKBkcLz4pEJNE4xOyEQvF2= MnTyNlU6PjB{OEK=
SK-N-ASCis24 NH7Zc|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTBwNUhihKnDueLCiUCuNVEh|ryP NWqxWWZ2OjV7NkCyPFI>
U87 Ml76S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjZPVhoOC13MDFOwG0> MmjoOFghcA>? MlK3[IVkemWjc3XzJINmdGxidnnhZoltcXS7IIfobYNpKGOjbjDi[UBmdmijbnPl[EBjgSC|aXzpZolvcW5? NGLsV3UzPTd3MEK3Ny=>
HCT116 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTHNVFZOC53LUKuOUDPxE1? NVPVdnBNPDkEoHlCpC=> NHHpSIxKSzVyPUGuO|PDqMLzwrCwMlIyyqEQvF2= MmS4NlU4PDZ5NkO=
HT-29 NHL5cZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlH4NE42NTJwNTFOwG0> M3POelQ5yqCqwrC= NV\NWHhXUUN3ME23MlLDqMLzwrCxMlA1yqEQvF2= NWTGRVJqOjV5NE[3OlM>
Caco2 M2G3TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzaRo9WOC53LUKuOUDPxE1? NEe0NXY1QMLiaNMg MoPRTWM2OD15LkK2xsDDucLiMT62POKh|ryP M2XQdFI2PzR4N{[z
COLO 205 NUnKZnJ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVv4bI1HOC53LUKuOUDPxE1? NXXiTnVxPDkEoHlCpC=> NFnreIlKSzVyPUGuOlHDqMLzwrCwMlAzyqEQvF2= MmDaNlU4PDZ5NkO=
SW480 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTWNE42NTJwNTFOwG0> MWS0POKhcMLi MXzJR|UxRTRwOUNCpOKyyqByLkOzxsDPxE1? NHvsPIozPTd2Nke2Ny=>
HEK293T M2D3d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYmxMVUh|ryP MoX0OFjDqGkEoB?= MUfJR|UxRTJwNENCpOKyyqByLkC1xsDPxE1? NV\3e2wzOjV5NE[3OlM>
Hep3B  Mn[ySpVv[3Srb36gRZN{[Xl? MkfCNVAh|ryP MYe0POKhcMLi M3nVS5Jm\HWlZYOgeIhmKGWwaHHuZ4lv\yCnZn\lZ5Qhd2ZiQl3QMVY> MYOyOVY{OzV4NB?=
Hep3B  NI\JXYVHfW6ldHnvckBCe3OjeR?= NVTYfHFLOC5zLUGwJO69VQ>? NFn5NVMzPCCq MWrzeZBxemW|c3XzJJRp\SCneIDy[ZN{cW:wIH;mJIhmeGOrZHnuJI1TVkF? NVrHZXFVOjV4M{O1OlQ>
HEK293 NVi1Z2FjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLXTWM2OD15LkG0xsDDucLiMD6zOuKh|ryP MnryNlU3ODNzMkK=
DU145 NE\nVJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjNTWM2OD1{LkK4xsDDucLiMD6wOOKh|ryP MX:yOVYxOzF{Mh?=
HCT15 MknmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvxRZl7UUN3ME2wMlgyyqEEsdMgNE4xOcLizszN MUCyOVYxOzF{Mh?=
T47D NWD6TWl{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlP5TWM2OD1|LkG4xsDDucLiMD6xNeKh|ryP MnXxNlU3ODNzMkK=
SMMC-7721 MXXGeY5kfGmxbjDBd5NigQ>? NIjmS401OCEQvF2= MVG0PEBp NX:0cVIyTE2VTx?= M2TGNIlv\HWlZYOg{tNJOkG[IH\vZ4kh\m:{bXH0bY9v NXKyfGxjOjV3NESzOlE>
MDA-MB-231 M2Xvemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX:3NuKhcA>? NVfaR|N{UUN3ME2yNU4zyqEEsdMgOE4zyqEQvF2= MlH4NlU1QDZ{MUm=
MCF-7 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nOSlczyqCq NIDIWlZKSzVyPUGwMlnDqMLzwrCyMlHDqM7:TR?= MV:yOVQ5PjJzOR?=
Jurkat MnLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\0O|LDqGh? MnqzTWM2OD1zLkNCpOKyyqBzLkZCpO69VQ>? M2XON|I2PDh4MkG5
HeLa NHntSlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUSwUJJJPzMEoHi= NXnEVm8yUUN3ME2zMlnDqMLzwrCyMlPDqM7:TR?= MoPuNlU1QDZ{MUm=
MCF7  M2XWTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvwenQ2NTFyMDFOwG0> MUi3JIQ> M{flSolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MmK0NlU1PzJ4MUm=
K562 M1TTPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXu3NuKhcA>? M3zHUmlEPTB;MD6yPeKh|ryP MnLRNlUzQDJ4NUO=
K/VP.5 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE[wUpc4OsLiaB?= Moe1TWM2OD12LkpCpO69VQ>? NVftS|JMOjV{OEK2OVM>
SH-EP  Ml20SpVv[3Srb36gRZN{[Xl? NGOw[2gzOMLizsznM41t Mom1NlTDqGh? MXvpcoNz\WG|ZYOgeIhmKGW6cILld5Nqd25ib3[g[Y5ld2enbn;1d{BFTVCS NGjsfYszPTJ4MUm4NS=>
SCC25 NXS0SWVtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXqNlTDqGh? MVPJR|UxRTR|LkRCpOKyyqBzLkGyxsDPxE1? MWCyOVIzODd{OR?=
CAL27 NIW5WVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULQOpR1OjUEoHi= MmXjTWM2OD13Mj6xxsDDucLiMT6wPeKh|ryP NEf6enozPTJ{MEeyPS=>
FaDu Ml\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\KO|I1yqCq Mmf4TWM2OD1{NT64PeKhyrIEoEGuNVPDqM7:TR?= MmLCNlUzOjB5Mkm=
SCC25 MoG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWj0VmNWPDkEoHi= NEnNV2ZKSzVyPUKwMlg3yqEEsdMgNU4xP8LizszN MW[yOVIzODd{OR?=
CAL27 M2jQRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXi0POKhcA>? NITab41KSzVyPUG4MlI1yqEEsdMgNU4yPcLizszN Ml;BNlUzOjB5Mkm=
FaDu MnfTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjFOXdGPDkEoHi= NVLlUVNlUUN3ME22MlQ{yqEEsdMgNU4yO8LizszN MUmyOVIzODd{OR?=
SCC25 NHH0N5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFT0T2s4OsLiaB?= NEi4W4tKSzVyPUiuOFHDqMLzwrCxMlEyyqEQvF2= NH3N[3MzPTJ{MEeyPS=>
CAL27 NXHidlFIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWq3NuKhcA>? M3nVZmlEPTB;ND6yO:KhyrIEoEGuNVTDqM7:TR?= NULCSZRWOjV{MkC3Nlk>
FaDu M{j2Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVq3NuKhcA>? NFHLdVRKSzVyPUWuNFLDqMLzwrCxMlE2yqEQvF2= NWnkeoMzOjV{MkC3Nlk>
MCF-7 NW\wR21YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rKeFQ5yqCqwrC= M2e5dWROW09? MV;JR|UxRTdwMtMgxtHDqDBwONMg{txO M4DDeVI2OjF4M{e4
T-47D M16wOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2m2fFQ5yqCqwrC= MV3EUXNQ NHvv[HVKSzVyPUeuO:KhyrIEoECuO:Kh|ryP NHjTd2MzPTJzNkO3PC=>
MDA-MB-231 M3T4W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4qw[|Q5yqCqwrC= NWPFVmhzTE2VTx?= Mn\ZTWM2OD1zMj64xsDDucLiMT6wxsDPxE1? M17FPFI2OjF4M{e4
DU145 NH3S[mNCeG:ydH;zbZMhSXO|YYm= MkDQNVAuOTByIN88US=> MmTpPEBp NWPxW3J[TE2VTx?= M1XKbYlv\HWlZYOgZ4VtdCCmZXH0bEB{cWewaX\pZ4FvfGy7IHnuJIEhfmW{eTDsc5ch[2:wY3XueJJifGmxbh?= NHrC[5QzPTF2OU[4NS=>
DU145 stem-like NIPxb3FCeG:ydH;zbZMhSXO|YYm= MUKxNE0yODBizszN Mn;FPEBp NVPSV|ljTE2VTx?= Mk[zbY5lfWOnczDj[YxtKGSnYYToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NWftWZp7OjVzNEm2PFE>
DU145 M3HMRWZ2dmO2aX;uJGF{e2G7 MmHYNVAuOTByIN88US=> NE\EXFYzKGh? Mn74SG1UVw>? M1;0eolv[3KnYYPld{B1cGVicFPIT|Eh\XiycnXzd4lwdiCjbnSg[IVkemWjc3XzJJRp\SCyQ1jLNUBmgHC{ZYPzbY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MXiyOVE1QTZ6MR?=
DU145 stem-like NHzR[lZHfW6ldHnvckBCe3OjeR?= NVfkcW9wOTBvMUCwJO69VQ>? NXnMNY5DOiCq Mn\hSG1UVw>? NWLIcnh1cW6lcnXhd4V{KHSqZTDwR2hMOSCneIDy[ZN{cW:wIHHu[EBl\WO{ZXHz[ZMhfGinIIDDTGsyKGW6cILld5Nqd25iaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NGXtRpIzPTF2OU[4NS=>
UW228-3 NFPGTHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{TiWFAvODFvM{CwJO69VQ>? NF;v[Wc1QCCq M4T6TWROW09? M4jMRWlEPTB;MD65PeKh|ryP NELIR2ozPTFzOUG4OS=>
NSCs MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmO2NE4xOS1|MECg{txO MYS0PEBp NXjzW|Z{TE2VTx?= Mo[wTWM2OD1yLkOtN:Kh|ryP NF3VNpozPTFzOUG4OS=>
MKL-1  MlLYSpVv[3Srb36gRZN{[Xl? NV;aT41qOTBvMUCwNEBvVQ>? NV3TSo1mPCCm NUOwPVdQcW6mdXPld{B1cGViaX7keYN1cW:wIH;mJG1JSy2LIHX4dJJme3Orb36= MlfpNlUyOTZ5NUS=
MCF7 EV M3HGXWZ2dmO2aX;uJGF{e2G7 Ml34NVAuOTByIN88US=> NX3FZpZIOuLCiXi= M4r0OIlv\HWlZYOgdJJw\HWldHnvckBw\sLizsPINmFZ MmjCNlUxQDh{MEO=
MCF 7BMI1 MX\GeY5kfGmxbjDBd5NigQ>? M1ThTFExNTFyMDFOwG0> M1fIO|LjiImq MUPpcoR2[2W|IIDyc4R2[3Srb36gc4bDqM7|SELBXC=> MW[yOVA5QDJyMx?=
MCF7 EV M3\SRWZ2dmO2aX;uJGF{e2G7 M1zrcVExNTFyMDFOwG0> NY[3eHhxOuLCiXi= NHruXmFGXE:SIHnu[JVk\XNiQWTNJIFkfGm4YYTpc44> MmHCNlUxQDh{MEO=
MCF7 BMI1 Mn6zSpVv[3Srb36gRZN{[Xl? M2TaS|ExNTFyMDFOwG0> MnOyNwKBkWh? MUnFWG9RKGmwZIXj[ZMhSVSPIHHjeIl3[XSrb36= M{XRUlI2ODh6MkCz
HepG2 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGr4cpVFVVORwrC= MWrJR|UxRTNyLkG2xsDDucLiMD61NOKh|ryP NXPzdWlFOjVyN{izNVE>
MOLT-3 NWr3O2VpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXraO3FzTE2VT9Mg NHXteFhKSzVyPUCuNFUyyqEEsdMgNE4xODMEoN88US=> M3T4clI2ODd6M{Gx
HT1080 NWLZNYRwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnDNU0yODBizszN NXvlNHd5PC9{ND:0PEBp NGHjXoxFVVORwrC= M2\HRYlv\HWlZYOgZ4VtdCCmZXH0bEB{cWewaX\pZ4FvfGy7IHnuJIEhfmW{eTDsc5ch[2:wY3XueJJifGmxbh?= MV[yOVA4QDB4NB?=
HT1080 NFPpbY9HfW6ldHnvckBCe3OjeR?= M3zKNFAvODByMT2xNFAh|ryP NUi2[Hh7OS1{NDDo M3LTbGROW00EoB?= MXLpcoR2[2W|IICtdFU{MHOnckG1LUBqdiCkb4ToJJRqdWVvIHHu[EBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XJ? NHqyNIMzPTB5OEC2OC=>
HT1080 NFPZZplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfYblg{OC5yMECxMVExOCEQvF2= MXKyOEBp MWTEUXNQyqB? M1SxbINifXOnczDhckBqdmO{ZXHz[UBqdiC2aHWgcpVu[mW{IH;mJINmdGy|IHnuJGczN01uIIfobYxmKGSnY4LlZZNqdmdiUzDhcoQhTzFicHjhd4Uh[2WubIO= M1y2clI2ODd6ME[0
HD-MY-Z MmjlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXKyOE81QC95MjDo M{jwcWlEPTExvK6xNFAh|ryP NFv0XFUzPTB2OEKzOi=>
DOHH-2 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{Dzb|I1KGh? M2SzV2lEPTExvK6xNFAh|ryP NHvMN44zPTB2OEKzOi=>
DOHH-2 NWLVfmhIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIP3ZmY1QCCq NYLie4xGUUN3ME2xPU46yqEQvF2= NX3PTY5pOjVyNEiyN|Y>
DOHH-2 M1\PPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4C1bFczKGh? MoTZTWM2OD13wrFOwG0> NVW5R5ljOjVyNEiyN|Y>
REH M2PnVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUKyOEBp NHe5VW9KSzVyPUCuNFI4yqEQvF2= NYTuOmh1OjVyNEiyN|Y>
REH MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVe0PEBp MUXJR|UxRTBwMEG0xsDPxE1? MnLlNlUxPDh{M{[=
REH MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYC3NkBp NEfiSo1KSzVyPUCuNFE2yqEQvF2= M4HCeVI2ODR6MkO2
HH MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHMUWczPCCq MXPJR|UxRTFyND63xsDPxE1? MV[yOVA1QDJ|Nh?=
HH MoX4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWfQTJF[PDhiaB?= NXfr[nFOUUN3ME20PE43yqEQvF2= NXLZd|ZMOjVyNEiyN|Y>
HH MnP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjoRVBTPzJiaB?= M{m1VWlEPTB;MUSuO:Kh|ryP MojENlUxPDh{M{[=
HuT-78 NHTGfmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYD1SIh4OjRiaB?= NHjF[5RKSzVyPUmuN:Kh|ryP MVWyOVA1QDJ|Nh?=
HuT-78 MmTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWf2bVBMPDhiaB?= MXHJR|UxRTRwM9Mg{txO M2jsbVI2ODR6MkO2
HuT-78 NWCxTYJFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXRO|IhcA>? NHj0SXJKSzVyPUSuNuKh|ryP MX:yOVA1QDJ|Nh?=
OPM-2 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;6fYNXOjRiaB?= NYfkcHdIUUN3ME2yOE4yyqEQvF2= MnPJNlUxPDh{M{[=
OPM-2 NF;YUI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHZOFghcA>? MkDwTWM2OD12wrFOwG0> NG\4d5MzPTB2OEKzOi=>
OPM-2 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXm3NkBp MWTJR|UxRTFwM9Mg{txO M4LIPFI2ODR6MkO2
RPMI-8226 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHJZWMzPCCq NI\icZFKSzVyPUGwOk43yqEQvF2= NIHi[JYzPTB2OEKzOi=>
RPMI-8226 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;JS2M1QCCq NXfYUokxUUN3ME25NU4yyqEQvF2= NWfVV5FJOjVyNEiyN|Y>
RPMI-8226 NGDNSFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlj5O|IhcA>? NXjQflRwUUN3ME2xOE46yqEQvF2= M1mzT|I2ODR6MkO2
U-266 NGrQZoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonZNlQhcA>? NYjpRnNyUUN3ME24Ok4zyqEQvF2= NI\DUFIzPTB2OEKzOi=>
U-266 NULudWRnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rZUVQ5KGh? NEDyd3pKSzVyPU[4MlTDqM7:TR?= M3jMcFI2ODR6MkO2
U-266 NHWwVnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2C5cVczKGh? NHXTZYdKSzVyPUK3MlTDqM7:TR?= MlPSNlUxPDh{M{[=
Kelly M{Hud2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYqwMVExKM7:TR?= Mnn4O|LDqGh? M17WTmlEPTB;MT61NVjDqM7:TR?= NVr6elk6OjVyMEi5NFA>
SH-SY5Y  MlLCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGK3bmQxNTFyIN88US=> NWe3[lVLPzMEoHi= Mlf3TWM2OD1yLke1OOKh|ryPwrC= NHvQZVgzPTByOEmwNC=>
SK-N-AS MlzmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVywMVExKM7:TR?= NHO1OmU4OsLiaB?= MVvJR|UxRTFwN{GyxsDPxE4EoB?= NHO0WmUzPTByOEmwNC=>
SK-N-DZ MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULXRWgyOC1zMDFOwG0> M1;LUFczyqCq MmXqTWM2OD13LkS4OeKh|ryP NFLPXFEzPTByOEmwNC=>
HepG2 NXvkUXB4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU[3U|U6PDkEoHi= MVTEUXNQyqB? MYjJR|UxRTF|Lk[1xsDDucLiMD65NuKh|ryP MWCyOFk6PjF|Nh?=
A549 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTQc5R6PDkEoHi= Mlf6SG1UV8Li MnPpTWM2OD1{NEGuPeKhyrIEoEOxMlI{yqEQvF2= NGPjeokzPDl7NkGzOi=>
MCF7 MmrIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXu0POKhcA>? M1\ndmROW00EoB?= NEG3blFKSzVyPUixMlA6yqEEsdMgNVQvOjIEoN88US=> M2fYZlI1QTl4MUO2
HL-60  NGLmSIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXra[ndnPzMEoHi= MVTJR|UxRTBwMUNihKXPxE1? NIiw[5MzPDl7M{CxOC=>
HL-60[R] Ml7XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUC3NuKhcA>? MnjzTWM2OD1|LkGy5qCG|ryP M3ezVVI1QTl|MEG0
MIAPACA MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHHTVUxRTFwMzFCtUAxNjB|IN88US=> M2mx[|I1QTV|OEKx
MCF-7 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXPS2k2OD1yLkK1JOKyKDBwMTFOwG0> M1vLW|I1QTV|OEKx
HeLa NHzlZXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTHTVUxRTBwNkSgxtEhOC52IN88US=> M2fYXVI1QTV|OEKx
MO59K  M13EbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml25O{Bl M4m4VGlEPTB;MD6xO-KBjc7:TR?= MnvHNlQ6PTN3NkG=
MO59J MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzXO{Bl M1\wRmlEPTB;MD6x5qCG|ryP NFjBe48zPDl3M{W2NS=>
ME 180 M2nIUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHhdWk1QMLiaNMg MoK0TWM2OD16LkpCpOKyyqByLkRihKXPxE1? MW[yOFk2OzB{Nx?=
MCF-7 NI\U[41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWK0POKhcMLi M4TqZWlEPTB;MkOuPUDDuSByLkRihKXPxE1? NVzoVJVqOjR7NUOwNlc>
HeLa MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnoOFjDqGkEoB?= Mnm4TWM2OD12LkexJOKyKDFwNPMAie69VQ>? MX:yOFk2OzB{Nx?=
MDA-MB-453 NFX0[FRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLsTIJSPDkEoHlCpC=> M1GxPGlEPTB;MUKuOUDDuSByLki15qCG|ryP MmDjNlQ6PTNyMke=
MDA-MB-231 M1jHVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF31bYE1QMLiaNMg NY\LNnM5UUN3ME2yOE4zOiEEsTCyMlk16oDHzszN NF;DdoczPDl3M{CyOy=>
PC-3 MkW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVq0POKhcMLi NV7tWpZ7UUN3ME2xOE41KMLzIEOuNlPjiIYQvF2= NF;wZYYzPDl3M{CyOy=>
HT-29 NV3VemUyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUT3[XdyPDkEoHlCpC=> M{L3[GlEPTB;MkGuOFUhyrFiMz64O-KBjc7:TR?= NYHFTGJYOjR7NUOwNlc>
BGC-823 NXfzSJpzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHmXWJ5PDkEoHlCpC=> MVjJR|UxRTR|Lke0JOKyKDVwMURihKXPxE1? MVWyOFc6Ozh5Nx?=
HeLa M4LKfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV25emFvPDkEoHlCpC=> NEG4RmhKSzVyPUKwPU46OCEEsTCxN{41OiEkgJZOwG0> NVTxc|R{OjR5OUO4O|c>
A549 M4KzUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn22OFjDqGkEoB?= Mn65TWM2OD1zM{muOVQhyrFiNz6wOgKBjc7:TR?= MlPwNlQ4QTN6N{e=
HK-2 M3PNWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXO0POKhcMLi MVrJR|UxRTlwMUegxtEhOS53OPMAie69VQ>? M3TYe|I1Pzl|OEe3

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

体内試験 Etoposide administrated as a single agent is found to been ineffective in many xenografts growth, such as Heterotransplanted Hepatoblastoma NMHB1, and NMHB 2, [6] human neuroblastoma xenograft, [7] and human gastrointestinal cancer xenograft, [8] while the dose of 10 mg/kg i.p. Etoposide inhibits murine angiosarcoma cell ISOS-1 tumors in 36% of controls. [2] Etoposide induces tumor immunity in Lewis lung cancer. A single administration of 50 mg/kg Etoposide i.p., induces a 60% survival of C57B1/6 mice injected with Lewis lung cancer cell (3LL) over 60 days. About 40% of these surviving mice reject a subsequent challenge with 3LL, while none of control mice survive beyond 30 days. 3LL cells which have survived an 90% lethal concentration of Etoposide in vitro kill 75% of recipient mice, but 60% surviving mice reject challenge with 3LL. Splenocytes harvested from tumor rejecting mice protect naive mice injected with 3LL. [9]

お薦めの試験操作(参考用のみ)

キナーゼ試験:[5]
+ 展開

Topoisomerase II activity assay:

Nuclear extracts are prepared, and nuclei are isolated. The activity of topoisomerase II is calculated from the percentage of decatenation obtained. Tritiated kinoplast DNA (KDNA 0.22 μg) is used as a substrate. Etoposide and topoisomerase II are incubated for 30 min at 37 ℃ and are stopped with 1% sodium dodecyl sulfate (SDS) and proteinase K (100 μg/mL). The percentages of decatenation and inhibition of topoisomerase II by Etoposide are obtained.
細胞試験: [5]
+ 展開
  • 細胞株: Human glioma cell lines CL5
  • 濃度: 80 μg/mL
  • 反応時間: 1 hour
  • 実験の流れ: After the Etoposide treatment, cells are removed from the dish with phosphate-buffered saline (PBS) containing 0.03% trypsin and 0.27 mM ethylenediaminetetraacetic acid (EDTA) and are diluted into culture dishes in appropriate numbers to yield between 20 and 200 colonies. After 12 days, cultures are fixed with methanol-acetic acid, stained with crystal violet, and scored for colonies containing more than 50 cells. The standard errors are typically less than 15% of the mean value unless otherwise stated.
    (参考用のみ)
動物試験:[2]
+ 展開
  • 動物モデル: Murine angiosarcoma xenografts ISOS-1
  • 製剤: Saline
  • 投薬量: 10 mg/kg
  • 投与方法: i.p. every day for 5 days from day 7
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 100 mg/mL (169.9 mM)
Water Insoluble
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
5% DMSO+30% PEG 300+H2O
混合させたのち直ちに使用することを推奨します。
15mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 588.56
化学式

C29H32O13

CAS No. 33419-42-0
保管
in solvent
別名 VP-16, VP-16213

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (g) = 濃度 (mol/L) x 体積 (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03036904 Not yet recruiting Diffuse Large B-Cell Lymphoma|High Grade B-Cell Lymphoma Weill Medical College of Cornell University|Genentech, Inc.|Massachusetts General Hospital|M.D. Anderson Cancer Center February 6, 2017 Phase 1
NCT02432274 Recruiting Tumors|Solid Malignant Tumors|Osteosarcoma|Differentiated Thyroid Cancer (DTC) Eisai Limited|Eisai Inc. December 29, 2014 Phase 1|Phase 2
NCT02385110 Recruiting Leukemia M.D. Anderson Cancer Center September 23, 2015 Phase 2
NCT03007147 Not yet recruiting B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1|BCR-ABL1 Fusion Protein Expression|Minimal Residual Disease|Philadelphia Chromosome Positive|T Acute Lymphoblastic Leukemia|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Childhood Acute Lymphoblastic Leukemia Childrens Oncology Group|National Cancer Institute (NCI) July 2017 Phase 3
NCT03016871 Not yet recruiting CD (Cluster of Differentiation) 30-Positive Neoplastic Cells Present|Recurrent Hodgkin Lymphoma|Refractory Hodgkin Lymphoma City of Hope Medical Center|National Cancer Institute (NCI) June 2017 Phase 2
NCT03041311 Not yet recruiting Small Cell Lung Cancer G1 Therapeutics, Inc. May 2017 Phase 2

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問(FAQ)

  • 質問1:

    Regarding the Etoposide S1225, do you have any data of the inhibition sepcificity of this product? It will inhibit other enzymes other than TOP2A?

  • 回答:

    According to the available published data, the inhibition of Etoposide is specific to TOP2A. But there're also two papers showing that Etoposide could inhibit the p34cdc2 Kinase Activity: 1. http://cancerres.aacrjournals.org/content/52/7/1817.short ; 2. http://cancerres.aacrjournals.org/content/50/12/3761.short.

Topoisomeraseシグナル伝達経路

相関Topoisomerase製品

Tags: Etoposideを買う | Etoposide ic50 | Etoposide供給者 | Etoposideを購入する | Etoposide費用 | Etoposide生産者 | オーダーEtoposide | Etoposide化学構造 | Etoposide分子量 | Etoposide代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID